Fig. 2From: A pilot study of multi-antigen stimulated cell therapy-I plus camrelizumab and apatinib in patients with advanced bone and soft-tissue sarcomasKaplan–Meier estimates of progression-free survival. A Total patient population. B Group by administration schedule of MASCT-I. C Group by disease subtype. NR, not reachedBack to article page